XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.23.3

(LOSS) EARNINGS PER SHARE | 9 Months Ended
--- | ---
Sep. 30, 2023
Earnings Per Share [Abstract] |
(LOSS) EARNINGS PER SHARE | (LOSS) EARNINGS PER SHARE (Loss) earnings per share attributable to Bausch Health Companies Inc. is calculated as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
(in millions, except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022
Net (loss) income attributable to Bausch Health Companies Inc. | $ | (378) |  |  | $ | 399 |  |  | $ | (553) |  |  | $ | 185 |
Basic weighted-average common shares outstanding | 365.4 |  |  | 362.5 |  |  | 364.5 |  |  | 361.8 |
Diluted effect of stock options and RSUs | — |  |  | 0.9 |  |  | — |  |  | 1.9 |
Diluted weighted-average common shares outstanding | $ | 365.4 |  |  | $ | 363.4 |  |  | $ | 364.5 |  |  | $ | 363.7 |
(Loss) earnings per share attributable to Bausch Health Companies Inc. |  |  |  |  |  |  |
Basic | $ | (1.03) |  |  | $ | 1.10 |  |  | $ | (1.52) |  |  | $ | 0.51 |
Diluted | $ | (1.03) |  |  | $ | 1.10 |  |  | $ | (1.52) |  |  | $ | 0.51 |
During the three and nine months ended September 30, 2023, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,075,000 and 2,931,000 common shares for the three and nine months ended September 30, 2023, respectively. During the three and nine months ended September 30, 2023, time-based RSUs, performance-based RSUs and stock options to purchase approximately 12,905,000 and 13,024,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 16,008,000 and 15,392,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2022, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration